Zelluna ASA Logo

Zelluna ASA

Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 08:00
Regulatory News Service
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday …
English 3.6 KB
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 1.0 MB
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 801.4 KB
2025-08-20 07:00
Earnings Release
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 5.6 KB
2025-08-14 12:00
Report Publication Announcement
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
English 1.7 KB
2025-07-03 12:07
Share Issue/Capital Change
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
English 3.4 KB
2025-06-25 16:19
Major Shareholding Notification
Disclosure of share transfer from Inven2 AS
English 711 bytes
2025-05-27 13:51
Major Shareholding Notification
Disclosure of Shareholding - Gjelsten Holding AS
English 1.2 KB
2025-05-27 13:38
Share Issue/Capital Change
ZLNA - New registered share capital
English 1.9 KB
2025-05-24 06:37
Share Issue/Capital Change
ZLNA - Issuance of shares through set-off of option exercise fee
English 2.3 KB
2025-05-08 05:00
Investor Presentation
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 1.3 MB
2025-05-08 05:00
Quarterly Report
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 664.4 KB
2025-05-08 05:00
Earnings Release
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 6.5 KB
2025-04-30 06:00
Report Publication Announcement
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
English 1.7 KB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 4.6 MB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.